CoreWeave's Interest Expense Hit $640 Million Last Quarter, 2.4 Times What It Was a Year Ago

CoreWeave’s Q2 interest expense surged to $640M (up from $267M a year earlier, ~2.4x), while revenue rose 112% YoY to ~$2.6B and backlog climbed to ~$104B. Management says it cut its weighted average cost of debt by ~300 bps (about $1.1B annualized savings), but the debt balance jumped to ~$35B, pushing blended interest cost to ~8.4% and implying $860M–$940M of Q3 interest expense (≈+41% at the midpoint). With capex guided to ~$19B–$23B for 2H (implying spending of ~$35B–$39B full-year) versus ~$5.5B cash at end-June, the key risk highlighted is the widening gap between the interest bill and adjusted operating income.

Analysis

The market should treat this less like a pure AI-growth story and more like a levered asset-financing trade. When a business needs to outspend operating profit by a wide margin to keep the growth curve intact, the equity behaves like residual claim on a financing machine: upside is driven by access to capital, not just demand. That makes the cost of debt the real hurdle rate, and at current funding levels each incremental spread widening matters more than another quarter of top-line surprise.

Second-order winners are the picks-and-shovels names that monetize AI buildout without carrying the balance-sheet burden, especially NVDA and, more broadly, the AI hardware basket. If CoreWeave slows issuance or pulls back capex, that does not kill AI demand; it just shifts spending toward better-capitalized hyperscalers and equipment vendors that can self-fund inventory and capex. The underappreciated loser set is high-yield credit and any private-market lender underwriting adjacent AI infrastructure deals, where this episode can force tighter covenants and higher equity cushions.

The next 1-3 months matter most around financing windows and the next earnings print: if interest expense keeps outrunning adjusted operating income, the equity de-rates further on dilution risk even without any insolvency headline. What would falsify the bearish view is a clear deceleration in interest expense growth, materially lower spreads on new debt, or evidence that capex can step down without impairing contracted revenue conversion. If those do not happen, the structural 6-18 month outcome is a slower, more expensive path to equity monetization, not a classic growth compounding setup.

Key Decisions for Investors

• Short CRWV into any post-financing or post-earnings strength; thesis is that equity remains hostage to WACC and dilution, with 1-3 month downside if new debt pricing stays near high single digits. Falsifier: management proves capex can normalize and Q3/Q4 interest expense flattens.
• Pair trade: long NVDA / short CRWV for 1-3 months to express AI demand versus balance-sheet risk. NVDA captures demand for compute with no refinancing overhang; CRWV bears the cost of funding that demand. Best if AI capex headlines stay strong but credit spreads stay sticky.
• Buy CRWV put spreads around the next financing update or earnings release if implied vol is not excessive. Use a defined-risk structure because the stock can squeeze on backlog rhetoric, but the payoff is asymmetric if the market focuses on interest expense versus operating income.
• Watch HYG and AI-adjacent credit names as a sentiment tell; if CRWV spreads wider, expect tighter underwriting across speculative-growth infrastructure deals. If HYG firms while Treasury yields fall, that would reduce near-term funding pressure and weaken the short thesis.